Exact Sciences Breaks Up With Pfizer -- Time to Buy?
Breaking up is hard to do, but not for Exact Sciences (NASDAQ: EXAS) and Pfizer (NYSE: PFE). Recently the partners let a partnership that was a lot more important to the diagnostics provider than the pharmaceutical giant come to an abrupt end.
Shares of Exact Sciences soared in 2020, but the stock has been under a lot of pressure this year. Underperforming sales of Cologuard, a non-invasive test for colon cancer, are partly to blame. Here's why the end of this relationship could work out well for Exact Sciences and its shareholders.
Image source: Getty Images.
Source Fool.com
